Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Estrogen Receptor Agonist Market size was valued at USD 4.63 billion in 2024 and is set to exceed USD 12 billion by 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of estrogen receptor agonist is evaluated at USD 5.21 billion.
This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.
Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.
Estrogen Receptor Agonist Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Osteoporosis 18.3% of people worldwide were estimated to have osteoporosis in 2021. Hence, in order to treat osteoporosis, the demand is on a surge for estrogen receptor agonists. Raloxifene is the most common type of estrogen which is approved by FDA used for this treatment.
- Rise in Women Suffering from PCOS Between 4% and 20% of women worldwide were believed to have PCOS in 2022. Further, PCOS have a huge adverse effect on female leading to irregular period and acne. Hence, polycystic ovary syndrome treatment on timely basis is necessary. Therefore, in order to control menstrual cycles in PCOS patients, oral contraceptives (OCs; with combined estrogen and progestin) are the most widely used form of medication.
- Surge in the Application of Estrogen in Asthma There has been growing research on the use of estrogen receptor agonist in the treatment of asthma. Beyond the reproductive system, estrogen plays a variety of tasks in both males and females, including controlling inflammation, intracellular calcium levels, and cell proliferation and differentiation. One of the characteristics of asthma is the infiltration of inflammatory cells such as lymphocytes, monocytes/macrophages, neutrophils, and eosinophils into the airways, particularly eosinophilic infiltration. Hence, it is poised that the estrogen receptor agonist would be used. Hence, further, the investment in research activities on this topic is anticipated to rise in order to prove the conclusion.
Challenges
- High Cost of Treatment
- Lack of Processionals who are Skilled in this Field – The use of estrogen receptor agonists is a new form of treatment on which still research is going on for its use to treat different diseases. Hence, not a large number of people are aware of this treatment. Also, since it is not popular enough there is a lack of professionals, especially in rural regions. Hence, this factor is projected to hinder the estrogen receptor agonist market growth.
- Adverse Effect of Estrogen Receptor Agonist
Estrogen Receptor Agonist Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 4.63 billion |
|
Forecast Year Market Size (2037) |
USD 12 billion |
|
Regional Scope |
|
Estrogen Receptor Against Segmentation
Route of Administration (Oral, Parental)
Estrogen receptor agonist market from the oral segment is anticipated to garner the highest revenue by the end of 2037. This segment growth is estimated to boost on account of its cost efficiency. Since parenteral drugs must be sterile and isotonic, the oral pharmaceuticals on the market are less expensive, which results in financial savings for the patient. Moreover, oral medication gets absorbed at a faster rate. Hence, they are most preferred.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
The hospital pharmacies segment in the estrogen receptor agonist market is set to have noteworthy growth over the forecast period. Most of estrogen receptor agonist drugs are prescribed by the doctors. Hence, the pharmacies attached to the hospitals are estimated to satisfy the growing demand for this medication.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Indication Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportEstrogen Receptor Agonist Industry - Regional Synopsis
APAC Market Statistics
Asia Pacific industry is predicted to dominate majority revenue share by 2037, backed by the growing geriatric population in this region. In Asia and the Pacific region, one in four persons is expected to be older than 60 by 2050. Moreover, this transition is expected to happen relatively quickly in several nations, such as the People's Republic of China, Sri Lanka, Thailand, and Viet Nam. Hence, the demand for estrogen receptor agonist is poised to grow. Old people are prone to various diseases such as cardiovascular disease, asthma, and more. Hence, in order to treat or prevent the growth of disease, the market is estimated to grow.
North American Market Forecast
The North America estrogen receptor agonist market is projected to have significant growth over the forecast period. The market in this region is poised to grow on account of rising cases of cancer.
Companies Dominating the Estrogen Receptor Agonist Landscape
- AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- ESTRIGENIX
- Karo Healthcare AB
- Merck KGaA
- Vivesto AB
- Oncternal Therapeutics
- Pfizer Inc.
- Tocris Bioscience
- Tokyo Chemical Industry Co., Ltd
In the News
- Positive high-level findings from the FLAURA2 Phase III trial showed that Tagrisso (osimertinib) from AstraZeneca improved progression-free survival (PFS) among individuals with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) more significantly when combined with chemotherapy than when used alone.
- On Thursday, October 27, and Friday, October 28, at the Grand Hyatt at San Francisco Airport, located at 55 South McDonnell Road in San Francisco, Estrigenix Therapeutics, Inc. presented new research on hormone replacement treatment.
Author Credits: Radhika Pawar
- Report ID: 4982
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
